NCJ Number
248882
Date Published
May 2015
Length
76 pages
Annotation
As part of the evaluation of the U.S. Justice Department's Defending Childhood Demonstration Program - a national initiative to counter the occurrence and harms of children's exposure to violence - this report on six of the eight demonstration sites summarizes implementation strategies, lessons learned, and promising practices.
Abstract
There were overarching themes evident in the different strategies the sites chose to pursue. These themes pertain to prevention programs (universal and targeted prevention); intervention with children exposed to violence (screening and assessment, treatment, and case management and advocacy); community and professional awareness and education; and interagency collaboration (collaborative bodies, system infrastructure, and capacity building). Some other themes pertain to tribal site and tradition, the special needs of rural sites, local politics, and the management of transitions. The 58 recommendations presented were developed through interviews with staff and stakeholders at each site, the technical assistance providers, and some grant managers of the Office of Juvenile Justice and delinquency Prevention (OJJDP). The recommendations are categorized by the parties to whom they are directed. These include jurisdictions interested in replicating a demonstration site's program, tribal communities, funding providers, technical assistance providers, and researchers and evaluators. 11 tables and appended aggregate program outputs by year, process evaluation stakeholder interview protocol, and sample quarterly implementation report
Date Published: May 1, 2015
Downloads
Similar Publications
- Fraud Victimization Across the Lifespan: Evidence on Repeat Victimization Using Perpetrator Data
- Atlanta Youth Count 2018 Community Report: The Prevalence of Sex and Labor Trafficking Among Homeless Youth in Metro Atlanta
- Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials